Gentian Diagnostics AS (GENT) - Total Assets
Based on the latest financial reports, Gentian Diagnostics AS (GENT) holds total assets worth Nkr258.54 Million NOK (≈ $27.21 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gentian Diagnostics AS - Total Assets Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's total assets have evolved over time, based on quarterly financial data. Also see Gentian Diagnostics AS stock valuation for the company's overall valuation and market capitalisation.
Gentian Diagnostics AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Gentian Diagnostics AS's total assets of Nkr258.54 Million consist of 71.3% current assets and 28.7% non-current assets. Review GENT current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 41.0% |
| Accounts Receivable | Nkr24.27 Million | 9.4% |
| Inventory | Nkr54.14 Million | 20.9% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GENT share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gentian Diagnostics AS's current assets represent 71.3% of total assets in 2025, an increase from 62.3% in 2013.
- Cash Position: Cash and equivalents constituted 41.0% of total assets in 2025, up from 12.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 20.9% of total assets.
Gentian Diagnostics AS Competitors by Total Assets
Key competitors of Gentian Diagnostics AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A
SHE:300760
|
China | CN¥59.27 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥916.43 Million |
|
Brainsway Ltd
NASDAQ:BWAY
|
USA | $121.97 Million |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
USA | $272.12 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
Gentian Diagnostics AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.40 | 5.38 | 12.93 |
| Quick Ratio | 3.81 | 3.85 | 11.42 |
| Cash Ratio | 3.10 | 2.81 | 0.00 |
| Working Capital | Nkr150.20 Million | Nkr131.85 Million | Nkr170.79 Million |
Gentian Diagnostics AS - Advanced Valuation Insights
This section examines the relationship between Gentian Diagnostics AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.93 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | Nkr258.54 Million |
| Market Capitalization | $61.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gentian Diagnostics AS's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gentian Diagnostics AS's assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gentian Diagnostics AS (2013–2025)
The table below shows the annual total assets of Gentian Diagnostics AS from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr258.54 Million ≈ $27.21 Million |
+12.57% |
| 2024-12-31 | Nkr229.66 Million ≈ $24.17 Million |
+26.86% |
| 2023-12-31 | Nkr181.04 Million ≈ $19.05 Million |
-3.60% |
| 2022-12-31 | Nkr187.79 Million ≈ $19.76 Million |
-11.33% |
| 2021-12-31 | Nkr211.79 Million ≈ $22.29 Million |
-9.98% |
| 2020-12-31 | Nkr235.26 Million ≈ $24.76 Million |
+3.56% |
| 2019-12-31 | Nkr227.18 Million ≈ $23.91 Million |
-11.94% |
| 2018-12-31 | Nkr257.98 Million ≈ $27.15 Million |
+25.70% |
| 2017-12-31 | Nkr205.23 Million ≈ $21.60 Million |
+66.91% |
| 2016-12-31 | Nkr122.96 Million ≈ $12.94 Million |
+23.01% |
| 2015-12-31 | Nkr99.96 Million ≈ $10.52 Million |
+418.67% |
| 2014-12-31 | Nkr19.27 Million ≈ $2.03 Million |
+36.01% |
| 2013-12-31 | Nkr14.17 Million ≈ $1.49 Million |
-- |
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more